IPO Listed
Braveheart Bio IPO
US$383m raised
NASDAQ: BRVE · US$18.00 cash per share
Advisers
Lead managers
- Bookrunner
- TD Securities (as TD Cowen)
- Legal adviser
- Issuer
- Braveheart Bio
- Issuer based in
- United States
- Listed
- 6 Aug 2026
- Sector
- Biotech
- Tags
- Biotech, Cardiovascular, Drug Development
In the league tables
Similar deals
- Kardigan IPO Jun 2026 · US$400m · Biotech
- Eikon Therapeutics IPO Feb 2026 · US$381m · Oncology
- Korsana Biosciences placement Apr 2026 · US$380m · Biotech
- Generate Biomedicines IPO Feb 2026 · US$400m · Biotech
- Latigo Biotherapeutics IPO Aug 2026 · US$346m · Biotech
Sources
- 6 Aug 2026 Final IPO prospectus (424B4), Braveheart Bio, Inc. sec.gov
- 7 Aug 2026 Goodwin Advises Braveheart Bio on $439.9 Million Closing of Upsized Initial Public Offering goodwinlaw.com





